|
It was reported that during a clinical study atrial fibrillation (afib) case, the patient suffered complete heart block requiring surgical intervention.Patient received an index cardiac ablation for ventricular tachycardia.On (b)(6) 2026, patient experienced complete heart block (ae#1), categorized as moderate and serious, defined by hospitalization with an admission date of (b)(6) 2026 and a discharge date of (b)(6) 2026.Relationship to study device is probable (navistar thermocool and optrell catheters) and relationship to the index study procedure is probable.The adverse event is anticipated.The outcome is resolved with an end date of (b)(6) 2026.Intervention was surgery (upgrade to a crt-d "[cardiac resynchronization therapy defibrillator]" system.Patient had already a 1 chamber -icd "[implantable cardioverter-defibrillator]").
|
|
E1.Initial reporter phone: (b)(6).An analysis of the product could not be performed since a physical sample was not received for evaluation.A manufacturing record evaluation was performed for the finished device number lot 31599752m and no internal actions related to the complaint were found during the review.As part of our company quality system process, all devices are manufactured, inspected, and distributed to approved specifications.This report is being submitted pursuant to the provisions of 21 cfr, part 803.This report may be based on information which has not been investigated or verified prior to the required reporting date.This report does not reflect a conclusion by biosense webster, inc., or its employees that the report constitutes an admission that the product, biosense webster, inc., or its employees caused or contributed to the potential event described in this report.If information is obtained that was not available for the initial report, a follow-up report will be filed as appropriate.Manufacturer's reference number: (b)(4).
|